HIVE vs BTBT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 26, 2026

HIVE

37.0
AI Score
VS
HIVE Wins

BTBT

33.6
AI Score

Investment Advisor Scores

HIVE

37score
Recommendation
SELL

BTBT

34score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE BTBT Winner
Revenue 60.04M 79.12M HIVE
Net Income -253.88M -142.91M HIVE
Net Margin -422.9% -180.6% HIVE
ROE -64.2% -33.8% HIVE
ROA -20.5% -15.5% HIVE
Total Assets 1.24B 924.64M BTBT
Cash 83.56M 208.04M HIVE
Current Ratio 1.51 1.96 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +7.2% · 3M: -13.8% BTBT 1M: +16.2% · 3M: -7.2%

Current Technical Phase

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.7%) with fading momentum, RSI 44

RSI (14): 44.2 · Price: $2.92

BTBT

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -0.4%) with fading momentum, RSI 49

RSI (14): 49.3 · Price: $1.62

Fundamentals Snapshot

Metric HIVE BTBT
Market Cap — —
Forward P/E -5.7 -10.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.7% 0.3%
Gross Margin 0.4% 0.6%
Operating Margin -0.6% -2.4%
EPS -1.39 -0.84
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.